
|Videos|October 29, 2021
Dr. Swerdloff on testosterone capsule for hypogonadal men
Author(s)Urology Times staff
“Most importantly, for the safety [of the] study…it looks like the medication has no really concerning adverse effects,” says Ronald Swerdloff, MD.
Advertisement
In this video, Ronald Swerdloff, MD, discusses the takeaways of the study, “Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men,” presented at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Swerdloff is a professor of medicine and senior investigator at The Lundquist Institute, Harbor-UCLA Medical Center and David Geffen School of Medicine, University of California, Los Angeles.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










